BackEiger BioPharmaceuticals Overview

Eiger BioPharmaceuticals Net Tangible Assets

Track Eiger BioPharmaceuticals's net tangible assets ($-14M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$-14.46M
126.14% YoYΔ $-69.77M vs prior year quarter

Peer average / median

Loading

Eiger BioPharmaceuticals Net Tangible Assets History

Loading

Eiger BioPharmaceuticals vs. peers: Net Tangible Assets Comparison

Loading

Eiger BioPharmaceuticals Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eiger BioPharmaceuticals (EIGRQ) FAQ

As of the most recent data (December 2023), EIGRQ shows a net tangible assets of $-14M. That compares with $55M in the prior-year period — down 126.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EIGRQ's net tangible assets is now $-14M (was $55M) — a 126.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Eiger BioPharmaceuticals is outperforming or lagging.

Tracking EIGRQ's net tangible assets over time shows whether Eiger BioPharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-14M That compares with $55M in the prior-year period — down 126.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Eiger BioPharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $-14M) with ownership activity and broader fundamentals.

Eiger BioPharmaceuticals's net tangible assets is $-14M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.